Return to homepagePandemic Pact

Comparing Ways for Patients and Clinics to Improve Blood Pressure Control

  • Funded by Patient-Centered Outcomes Research Institute
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Known Financial Commitments (USD)

    $357,993

  • Funder

    Patient-Centered Outcomes Research Institute

  • Principal Investigator

    MD. Mark Pletcher

  • Research Location

    United States of America

  • Lead Research Institution

    The Regents of the University of California-San Francisco

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

It is unknown how medicines for high blood pressure affect COVID-19 infection. With this enhancement, the research team will look at two types of medicines to treat high blood pressure. One type is angiotensin converting enzyme inhibitors, or ACEIs. The other type is angiotensin receptor blockers, or ARBs. The team will look at patient health records to learn how taking an ACEI, ARB, or other blood pressure medicines affects Patients' risks for infection with COVID-19 How severe the infection is